DK2310003T3 - Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv - Google Patents
Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv Download PDFInfo
- Publication number
- DK2310003T3 DK2310003T3 DK09769327.9T DK09769327T DK2310003T3 DK 2310003 T3 DK2310003 T3 DK 2310003T3 DK 09769327 T DK09769327 T DK 09769327T DK 2310003 T3 DK2310003 T3 DK 2310003T3
- Authority
- DK
- Denmark
- Prior art keywords
- delipidation
- carnitine
- palmitoyl
- transferase
- inhibitors
- Prior art date
Links
- 230000015961 delipidation Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000001537 neural effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7631608P | 2008-06-27 | 2008-06-27 | |
| PCT/EP2009/057983 WO2009156479A1 (en) | 2008-06-27 | 2009-06-25 | Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2310003T3 true DK2310003T3 (da) | 2020-05-18 |
Family
ID=41036746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09769327.9T DK2310003T3 (da) | 2008-06-27 | 2009-06-25 | Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8741949B2 (da) |
| EP (1) | EP2310003B1 (da) |
| AU (1) | AU2009264237B2 (da) |
| CA (1) | CA2766282C (da) |
| DK (1) | DK2310003T3 (da) |
| WO (1) | WO2009156479A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| GB201116131D0 (en) * | 2011-09-19 | 2011-11-02 | Epistem Ltd | Probe |
| US20180216113A1 (en) * | 2015-08-20 | 2018-08-02 | The Regents Of The University Of California | Methods for reducing proteotoxicity |
| CA3086945A1 (en) * | 2016-12-29 | 2018-07-05 | Meta-Iq Aps | Variants of 2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid for use in the treatment, prevention and/or amelioration of brain diseases |
| AU2018289303B2 (en) | 2017-06-20 | 2023-12-21 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| WO2019089940A1 (en) * | 2017-11-01 | 2019-05-09 | Pairnomix, Llc | Methods of treating epilepsy and related neurological conditions |
| WO2020081361A1 (en) | 2018-10-17 | 2020-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| WO2022233942A1 (en) | 2021-05-04 | 2022-11-10 | 2N Pharma Aps | Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4337267A (en) * | 1980-08-25 | 1982-06-29 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids, their use and medicaments containing them |
| FR2739031B1 (fr) | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique |
| US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
| EP0889723B1 (de) | 1996-03-25 | 2002-06-05 | LTS LOHMANN Therapie-Systeme AG | Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren |
| AUPO379596A0 (en) | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
| WO2003037323A2 (en) | 2001-10-26 | 2003-05-08 | MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction |
| AU2004248187A1 (en) | 2003-06-12 | 2004-12-23 | University Of Colorado System Technology | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors |
| WO2007116074A1 (en) | 2006-04-10 | 2007-10-18 | Mintails Limited | Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions |
| GB0719248D0 (en) * | 2007-10-03 | 2007-11-14 | Generics Uk Ltd | Compounds and methods for pharmaceutical use |
-
2009
- 2009-06-25 DK DK09769327.9T patent/DK2310003T3/da active
- 2009-06-25 AU AU2009264237A patent/AU2009264237B2/en not_active Ceased
- 2009-06-25 US US13/001,422 patent/US8741949B2/en active Active
- 2009-06-25 WO PCT/EP2009/057983 patent/WO2009156479A1/en active Application Filing
- 2009-06-25 EP EP09769327.9A patent/EP2310003B1/en active Active
- 2009-06-25 CA CA2766282A patent/CA2766282C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8741949B2 (en) | 2014-06-03 |
| EP2310003B1 (en) | 2020-02-12 |
| US20110178172A1 (en) | 2011-07-21 |
| WO2009156479A1 (en) | 2009-12-30 |
| AU2009264237A1 (en) | 2009-12-30 |
| AU2009264237B2 (en) | 2016-04-14 |
| CA2766282C (en) | 2021-03-02 |
| EP2310003A1 (en) | 2011-04-20 |
| CA2766282A1 (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2310003T3 (da) | Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv | |
| DK2796469T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser | |
| DK2445502T4 (da) | Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser | |
| DK2240135T3 (da) | Apparat til behandling af fedme og reflukssygdom | |
| DK1685834T3 (da) | Anvendelse af pinolensyre til behandling af obesitet | |
| DK2894165T3 (da) | Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser | |
| DK2463283T3 (da) | Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme | |
| DK3067066T3 (da) | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom | |
| DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
| BRPI0917130A2 (pt) | biomarcadores para tratamento anti-tnf de colite ulcerativa e transtornos relacionados | |
| BRPI0810561A2 (pt) | métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13. | |
| ATE434620T1 (de) | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen | |
| DK2726511T3 (da) | Sammensætninger, anvendelser og fremgangsmåder til behandling af stofskiftesygdomme og -lidelser | |
| DK2114447T3 (da) | Forebyggelse og behandling af subkliniks pcvd | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| BRPI0811265A2 (pt) | Tratamento de sinucleinopatias | |
| BRPI0807987A2 (pt) | Terapia de combinação para tratamento de distúrbios imunes. | |
| DK2445912T3 (da) | Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme | |
| DK2451482T3 (da) | Kombinationsterapi til behandlingen af diabetes | |
| DK2056842T3 (da) | Modificeret galactosylceramid til behandling af cancerøse sygdomme | |
| DK3135672T3 (da) | Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme | |
| DK2307000T3 (da) | Kombination af pilocarpin og methimazol til behandling af charcot-marietooth-sygdom og beslægtede lidelser | |
| DK2432798T3 (da) | 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme | |
| BRPI0816712A2 (pt) | terapia de intervalo para o tratamento de tinnitus | |
| EP2139475A4 (en) | USE OF PDE7 INHIBITORS IN THE TREATMENT OF |